Methods for determining stages and progression of amyotrophic lateral sclerosis - Patents.com

Immune cell profiling using flow cytometry and mass cytometry offers a quantitative method for diagnosing ALS and tracking disease progression, enabling targeted therapies and improving treatment efficacy by identifying specific immune cell subpopulations.

JP2024543827APending Publication Date: 2024-11-26THE GENERAL HOSPITAL CORP
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024526790
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-11
Filing Date
2022-11-14
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Current methods for diagnosing and monitoring amyotrophic lateral sclerosis (ALS) are challenging due to the difficulty in early detection and lack of reliable biomarkers for tracking disease progression, leading to subjective and semi-quantitative clinical markers that are not validated for predicting prognosis or treatment efficacy.

Method used

The use of immune cell profiling through flow cytometry and mass cytometry to assess the immune status of patients by quantifying white blood cell subsets, including CD4+ lymphocytes, CD8+ lymphocytes, regulatory T cells, B cells, NK cells, and granulocytes, to determine an immune signature that can define the stage and progression of ALS, informing clinical decision-making and therapy selection.

Benefits of technology

Provides a quantitative and reliable method for diagnosing ALS and monitoring disease progression, enabling targeted therapies and improving treatment efficacy through immune cell therapies and immunomodulatory agents, such as riluzole and edarvarone, by identifying specific immune cell subpopulations and their changes over time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543827000001_ABST
    Figure 2024543827000001_ABST
Patent Text Reader

Abstract

The invention features a method that includes characterizing a white blood cell sample from a patient using cytometry (e.g., CyTOF); a deficiency of regulatory or suppressive immune cells and an increase in activated immune cells in the sample compared to a healthy sample indicates that the patient has amyotrophic lateral sclerosis (ALS). TIFF2024543827000002.tif101134
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Claiming priority This application claims the benefit of U.S. Provisional Patent Application No. 63 / 278,114, filed November 11, 2021. The entire contents of the aforementioned application are incorporated herein by reference. [Background technology]

[0002] 2. Background of the Invention The present invention relates to methods for the diagnosis of amyotrophic lateral sclerosis (ALS) and for monitoring ALS progression, as well as methods for the treatment of the disease.

[0003] Amyotrophic lateral sclerosis, or ALS, is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control. ALS often begins with muscle spasms and weakness in the hands and feet or slurred speech. Eventually, ALS affects control of the muscles needed for movement, speech, feeding, and breathing. There is no cure, and the disease is fatal. ALS affects the nerve cells (motor neurons) that control voluntary muscle movements, such as walking and talking. ALS gradually causes the motor neurons to deteriorate and eventually die. Motor neurons are threaded throughout the body, from the brain through the spinal cord to the muscles. When motor neurons are damaged, they stop sending messages to the muscles, and as a result, the muscles stop working. In 5-10% of cases, the condition is hereditary; in others, the cause is unknown but may involve a complex interaction between genetic and environmental factors (called "sporadic ALS"). Early diagnosis is typically difficult because ALS can mimic other neurological diseases.Currently, tests to exclude other neurological conditions can include electromyogram to detect abnormalities in electrical activity in muscle contraction and relaxation, nerve conduction test to measure the ability of nerves to send action potentials, magnetic resonance imaging (MRI) imaging of the brain and spinal cord to exclude conditions caused by spinal tumors and herniated disks, blood and urine tests for other diseases and conditions, and muscle biopsy to exclude muscle diseases.There is a need in the art for a method to identify the stage and progression of ALS. Summary of the Invention

[0004] The present invention provides methods and materials related to assessing immune system profile for amyotrophic lateral sclerosis (ALS). For example, the present application provides methods and materials for performing flow cytometry using white blood cell samples to determine the number of circulating white blood cell subsets to determine the immune status of a patient (e.g., human). In some cases, the immune status of a patient is determined by, for example, measuring the number of CD4+ lymphocytes, CD8+ lymphocytes, regulatory T cells, B cells, NK cells, granulocytes, etc., as disclosed herein. The immune status can be determined by quantifying each major category representative of white blood cells (e.g., granulocytes, NK cells, T cells, B cells, lymphocytes, etc., as disclosed herein).

[0005] Thus, the present invention relates to the use of immune cell proteomic signatures to define the stage and progression of ALS and to inform clinical decision-making regarding, inter alia, diagnosis, therapeutic targeting, therapy selection, monitoring of treatment efficacy, and prognosis.

[0006] The invention generally features a method that includes characterizing a white blood cell sample from a patient using cytometry (e.g., CyTOF); a deficiency in regulatory or suppressive immune cells and an increase in activated immune cells in the sample compared to a healthy sample indicates that the patient has amyotrophic lateral sclerosis (ALS).

[0007] In some embodiments, the sample is incubated with an antibody that specifically binds to granulocytes, monocytes, dendritic cells, T cells, B cells, NK cells, immune-activated cells, or immune-suppressive cells. In one embodiment, the regulatory or suppressive immune cells include Treg, Breg, or M2 macrophage clusters. In some embodiments, the activated immune cells include T effector and B effector and NK effector cell clusters.

[0008] In some embodiments, the methods include calculating the number of immune cells and their percentage of the total leukocyte population of the sample using a pan-human leukocyte marker (eg, CD45).

[0009] In some embodiments, the cytometry is cell or mass cytometry.

[0010] In some embodiments, the methods include performing total RNA sequencing on the samples to define subpopulations of the leukocyte population; and TCR and BCR expression analysis, viral genomic analysis, and / or HLA analysis.

[0011] In some embodiments, the method comprises identifying a cluster of leukocytes in the sample. In some embodiments, the identifying comprises cluster analysis, linear regression analysis, linear discriminant analysis, and / or elastic net logistic analysis. In some embodiments, the cluster of leukocytes distinguishes between healthy individuals and individuals with ALS (such as late ALS or early ALS).

[0012] In some embodiments, the patient has a deficiency in Treg, Breg, or M2 macrophage clusters.

[0013] In some embodiments, the patient has an increase in activated immune cell clusters, T effector and B effector.

[0014] In some embodiments, the patient has an increase in activated NK effector clusters.

[0015] In some embodiments, the method further comprises administering to the patient a therapy for treating ALS. In some embodiments, the therapy is riluzole or edarvarone.

[0016] In some embodiments, FoxP3+B regulatory cells are less abundant in ALS patients.

[0017] In some embodiments, mature B cells comprising CD11c expression are increased in patients with lower ALSFRS-R compared to higher ALSFRS-R and healthy controls.

[0018] In some embodiments, CD4 T cells are increased in ALS patients.

[0019] In some embodiments, CD8 T cells are increased in ALS patients.

[0020] In some embodiments, activated CD4 T cells are elevated in ALS patients with lower ALSFRS-R compared to patients with higher ALSFRS-R and healthy controls.

[0021] In some embodiments, CD11c+ monocytes are increased in ALS patients.

[0022] In some embodiments, NK T cells are increased in ALS patients.

[0023] In some embodiments, activated B cells (CD19+ CD20+ IgD+ IgM+) are decreased in ALS patients.

[0024] In some embodiments, memory B cells (CD19+ CD20+ CD21+ CD27+) are decreased in ALS patients.

[0025] In some embodiments, activated CD4 T cells (CD27+ PD1+) are increased in ALS patients.

[0026] In some embodiments, CD8 T cells (CD27+ CD7+) are increased in ALS patients.

[0027] In some embodiments, CD4 T cells (CD25+ CD27+ CD39+) are increased in ALS patients with lower ALSFRS-R compared to ALS patients with higher ALSFRS-R and healthy controls.

[0028] In some embodiments, NK T cells are increased in ALS patients.

[0029] In some embodiments, the method includes determining the levels of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more markers listed in Figures 2, 8B, 10B, 12, 14B, and 15B.

[0030] In some embodiments, the sample comprises a phenotype depicted in clusters 387, 392, 394, 408, or 422.

[0031] In some embodiments, the sample comprises a phenotype depicted in clusters 951, 947, 961, 953, 945, 955, 954, 949, 944, 956, or 962.

[0032] In some embodiments, the sample comprises a phenotype depicted in clusters 21, 28, 44, 92, or 37.

[0033] In another aspect, the present invention provides a method for producing a method for manufacturing a pharmaceutical composition comprising: (a) determining whether a patient has ALS according to any of the preceding methods; (b) analyzing a second white blood cell sample from the patient according to any of the preceding methods; and (c) determining a deficiency in regulatory or suppressive immune cells and an increase in activated immune cells in the second sample. The present invention is characterized by a method comprising the steps of:

[0034] In some embodiments, the patient has an increased deficiency of Treg, Breg, or M2 macrophage clusters in the second sample compared to the sample obtained at an earlier time point.

[0035] In some embodiments, the patient has an increase in activated immune cell clusters, T effector and B effector, in the second sample compared to the earlier surveillance sample.

[0036] In some embodiments, the patient has an increase in activated NK effector clusters in the second sample compared to an earlier surveillance sample.

[0037] In some embodiments, the method further comprises administering to the patient a therapy for treating the ALS.

[0038] In some aspects, the therapy comprises immune cell therapy.

[0039] In some embodiments, the immunotherapy comprises administering B cells or Treg cells.

[0040] In some aspects, the therapy comprises administering an immunomodulatory agent.

[0041] In some embodiments, the immunomodulatory agent is Baracitinib or a Jak-Stat inhibitor.

[0042] In some embodiments, the patient has experienced a clinically meaningful decline from baseline in ALSFRS-R total score at the time the second sample is obtained.

[0043] In some embodiments, there are at least 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, or 14 weeks between obtaining the first sample and the second sample.

[0044] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.Methods and materials are described herein for use in this invention; other suitable methods and materials known in the art can also be used.Materials, methods, and examples are illustrative only and are not intended to be limiting.All publications, patent applications, sequences, and other references mentioned herein are incorporated by reference in their entirety.In case of discrepancy, the present specification, including definitions, will prevail.

[0045] The present invention provides several advantages and addresses unmet needs in ALS patient care. Current biomarkers for documenting or monitoring ALS progression rely on subjective or at best semi-quantitative clinical assessments (ALS-FRS scores) or blood markers, including neurofilament measurements, that have not been previously validated to predict prognosis, specific clinical outcomes, and / or treatment indicators. No biomarkers derived from serum, plasma, or cellular components of blood, cerebrospinal fluid (CSF), or other body tissues have been defined that can assist in quantitative monitoring of a patient's clinical ALS progression, define the impact of standard care or investigational therapies, and assist in the clinical decision to initiate specific standard care or investigational immunomodulatory or anti-inflammatory therapies. The methods and approaches described herein are relevant not only to the diagnosis of ALS, but also to other standard clinical / neurological findings.

[0046] To date, no immune signature has been identified in ALS to track disease progression. Although certain single immune cell populations (such as activated T cells) have been investigated as biomarkers, immune signatures that involve combined and simultaneous assessment with B cells, T cells, NK cells, monocytes, and neutrophils have not been defined. The methods described herein include focusing on closely evaluating B cell populations in the context of ALS. We have identified highly specific subpopulations of B cells and T cells that are differentially expressed between healthy controls and patients with ALS, as well as between healthy, high ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Scale), and low ALSFRS-R. These signature differences detailed herein define a set of disease progression markers that inform the diagnosis of ALS, the determination of disease stage, and the assessment of the effectiveness of standard care therapies such as riluzole and edarabarone, as well as the assessment of the effectiveness of investigational therapies and therapies in clinical trials to assess the safety and efficacy of these agents. Currently, there are no biomarkers for ALS that can be used for this purpose.

[0047] Moreover, as described herein, CD11c expression is surprisingly a distinguishing marker of B cells in ALS. CD11c+ B cells produce IL-10, a regulatory cytokine, even under optimal conditions. CD39 is an ectonucleotidase that is the rate-limiting enzyme in the conversion of ATP to immunoregulatory adenosine. Moreover, CD39+ B cell subsets are surprisingly distinguishing between ALS patients and healthy controls.

[0048] Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims. [Brief description of the drawings]

[0049] This disclosure contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0050] [Figure 1] The study design includes 30 ALS and 15 age / sex-matched controls. [Diagram 2] CyTOF antibody panel is shown. [Diagram 3] Data analysis of the force-directed layout of live cell clusters generated by X-shift clustering of the ALS dataset. Each color represents a different cluster. The distance between the clusters indicates their similarity. [Figure 4] Figures 4A, 4B, 4C, and 4D show differential abundance in CD45+ cells in an unpaired t-test. Volcano plots of CD45+ cell clusters are based on absolute abundance using a Student's unpaired t-test. The red dotted lines indicate the p-value (y-axis) and fold change (x-axis) thresholds; to be significant, a cluster must exceed both dotted lines. The size of the circle representing each cluster on the plot indicates the number of cells in that cluster. Two clusters were identified as differentially abundant via this unpaired t-test, however, clusters 416 and 396 both comprised less than 0.1% of live cells and were therefore removed from downstream analysis. [Diagram 5]Figure 1 shows the results of elastic net logistic regression of CD45+ cells. Elastic net waterfall plot of clusters (y-axis) with the top 30 regression coefficients (x-axis). Coefficients represent the log change in odds per unit increase. In the training model used, there is an increase in risk of the outcome as x increases. This can be converted to an odds ratio using (exp (x-value))*100%, where the percentage indicates that there is an increase (>100%) or decrease (<100%) in odds of the outcome for each unit increase in x. Within the training model used here, the graph indicates that healthy controls are assumed to have a higher probability of having more grey clusters, whereas ALS patients have a higher probability of having more black clusters. (*) indicates clusters that are less than 0.1% of CD45+ cells. Due to their small size, these clusters were not evaluated further. [Figure 6] 4 shows the results of the phenotypic profile of CD45+ cell clusters identified via elastic net logistic regression. [Figure 7] Results of linear discriminant analysis are shown: CD45+ healthy cells (n=6), ALS FRS29-39 (n=5), and ALS FRS40-47 (n=7). A linear discriminant analysis (LDA) model was constructed to rank up to three cluster combinations based on their ability to discriminate between healthy controls (N=6) and ALS FRS29-39 (N=5), followed by assessment of the distribution of ALS FRS40-47 (N=7). Using a discriminant function with high predictive accuracy, the three groups were projected onto the corresponding feature space to identify combinations of cell populations with a trend of ALS FRS40-47 toward healthy controls. LDA plots show the distribution of each group, with the center of the x-axis indicating the point where ALS FRS29-39 and healthy controls are maximally separated, and the y-axis reflects the counts (i.e., density estimates). The title of each plot indicates the cluster in the model. The accuracy of each model is indicated within the plot. [Figure 8]Figures 8A and 8B show clusters identified by linear discriminant analysis of CD45+ cells. Figure 8A shows scatter plots comparing healthy and ALS, and healthy, FRS 40-47, and FRS 29-29. The x-axis shows the group, and the y-axis shows the frequency of the cluster in CD45+ cells from each donor. The horizontal lines show the mean, and the error bars show the standard deviation. Figure 8B shows a parallel coordinate plot showing the phenotype of cluster 422. Along the x-axis are the markers on which the cluster was defined, and the y-axis shows the intensity of expression of each marker in the cluster. The red line represents cluster 422, and the grey lines show the expression of the other clusters in the study. The peaks represent the highest expression of that marker. Of the total 499480 clustered cells, 101894 cells constitute this cluster, which represents 4 20.4% of the clustered CD45+ cells. [Figure 9] Figure 9A, Figure 9B, Figure 9C, and Figure 9D show the abundance differences in B cells in an unpaired t-test. Volcano plots of B cell clusters are based on absolute abundance using a Student's unpaired t-test. The red dotted lines indicate the p-value (y-axis) and fold change (x-axis) thresholds; to be significant, a cluster must exceed both dotted lines. The size of the circle representing each cluster on the plot indicates the number of cells in that cluster. [Figure 10]Figures 10A and 10B show the difference in abundance in B cells. Cluster 962 is significantly enriched in patients with FRS > 40. Figure 10A shows a scatter plot comparing healthy and ALS, and healthy, FRS 40-47, and FRS 29-29. The x-axis shows the group, and the y-axis shows the frequency of the cluster in B cells from each donor. The horizontal lines show the mean, and the error bars show the standard deviation. Figure 10B shows a parallel coordinate plot showing the phenotype of cluster 962. Along the x-axis are the markers on which the cluster was defined, and the y-axis shows the intensity of expression of each marker in the cluster. The red line represents cluster 962, and the grey lines show the expression of the other clusters in the study. The peaks represent the highest expression of that marker. Of the total 27545 clustered cells, 1212 cells constitute this cluster, which represents 4.4% of the clustered B cells. Based on expression, the cluster is CD11blow CD11clow CD21+ CD24+ CD27+ CD39mid FoxP3+ HLADR+ IgG+. [Figure 11] Elastic net logistic regression results for B cell clusters are shown. Figure 11 shows an elastic net waterfall plot of clusters (y-axis) with the top 30 regression coefficients (x-axis). The coefficients represent the logarithmic change in odds per unit increase. In the training model used, there is an increase in risk of the outcome as x increases. This can be converted to an odds ratio using (exp (x-value))*100%, where the percentage indicates that there is an increase (>100%) or decrease (<100%) in odds of the outcome for each unit increase in x. Within the training model used here, the graph indicates that healthy controls are assumed to have a higher probability of having more grey clusters, whereas ALS patients have a higher probability of having more black clusters. (*) indicates clusters that are less than 0.5% of B cells. Due to their small size, these clusters were not evaluated further. [Figure 12]1 shows the results of the phenotypic profiles of B cell clusters identified via elastic net logistic regression. [Figure 13] Results of linear discriminant analysis are shown: healthy B cells (n=6), ALS FRS29-39 (n=5), and ALS FRS40-47 (n=7). A linear discriminant analysis (LDA) model was constructed to rank up to three cluster combinations based on their ability to discriminate between healthy controls (N=6) and ALS FRS29-39 (N=5), followed by assessing the distribution of ALS FRS40-47 (N=7). Using a discriminant function with high predictive accuracy, the three groups were projected onto the corresponding feature space to identify cell population combinations with a trend of ALS FRS40-47 toward healthy controls. LDA plots show the distribution of each group, with the center of the x-axis indicating the point where ALS FRS29-39 and healthy controls are maximally separated, and the y-axis reflects the counts (i.e., density estimates). The title of each plot indicates the cluster in the model. The accuracy of this model for the B cell cluster was low, as shown in the table. [Figure 14] Figure 14A and Figure 14B show the results of clusters identified by linear discriminant analysis of B cells. Figure 14A shows scatter plots comparing healthy and ALS, and healthy, FRS 40-47, and FRS 29-29. The x-axis shows the group, and the y-axis shows the frequency of clusters in B cells from each donor. The horizontal lines show the mean value, and the error bars show the standard deviation. Figure 14B shows a parallel coordinate plot showing the phenotype of cluster 955. Along the x-axis are the markers on which the clusters were defined, and the y-axis shows the intensity of expression of each marker in the cluster. The red line represents cluster 955, and the grey lines show the expression of the other clusters in the study. The peaks represent the highest expression of that marker. Of the total 27545 clustered cells, 1333 cells constitute this cluster, which represents 4.85% of the clustered B cells. Based on expression, the cluster is CD11c+ CD39mid HLADR+ IgD+ IgM+. [Figure 15]Figures 15A and 15B show the results of clusters identified by linear discriminant analysis of B cells. Figure 15A shows scatter plots comparing healthy and ALS, and healthy, FRS 40-47, and FRS 29-29. The x-axis shows the group, and the y-axis shows the frequency of the cluster in B cells from each donor. The horizontal lines show the mean value, and the error bars show the standard deviation. Figure 15B shows a parallel coordinate plot showing the phenotype of cluster 960. Along the x-axis are the markers on which the cluster was defined, and the y-axis shows the intensity of expression of each marker in the cluster. The red line represents cluster 960, and the grey lines show the expression of the other clusters in the study. The peaks represent the highest expression of that marker. Of the total 27545 clustered cells, 5741 cells constitute this cluster, which represents 20.9% of the clustered B cells. Based on expression, the cluster is CD21+ CD24+ CD25+ CD27+ CD39mid CD69+ FoxP3low HLADR+ IgD+ IgM+. [Figure 16] Figures 16A and 16B show the results of CD45+ cell abundance differences in an unpaired t-test. Volcano plot of CD45+ cell clusters based on absolute abundance using a Student's unpaired t-test. The red dotted lines indicate the p-value (y-axis) and fold change (x-axis) thresholds; to be significant, a cluster must exceed both dotted lines. The size of the circle representing each cluster on the plot indicates the number of cells in that cluster. [Figure 17]Figure 1 shows the results of elastic net logistic regression of CD45+ cell clusters. Elastic net waterfall plot of clusters (y-axis) versus regression coefficients (x-axis). Coefficients represent the log change in odds increase per unit. In the training model used, there is an increase in risk of the outcome as x increases. This can be converted to an odds ratio using (exp (x-value)) * 100%, where the percentage indicates that there is an increase (>100%) or decrease (<100%) in odds of the outcome for each unit increase in x. Within the training model used here, the graph shows that healthy controls are assumed to have a higher probability of having more grey clusters, whereas ALS patients have a higher probability of having more black clusters. [Figure 18] Figures 18A and 18B show the results of elastic net logistic regression of CD45+ cell clusters where the clusters were >0.1% of total CD45+ cells. [Figure 19] Linear discriminant analysis results are shown for: CD45+ healthy cells (n=11), ALS FRS21-39 (n=17), and ALS FRS40-47 (n=11). A linear discriminant analysis (LDA) model was constructed to rank up to three cluster combinations based on their ability to discriminate between healthy controls (N=11) and ALS FRS21-39 (N=17), followed by assessment of the distribution of ALS FRS40-47 (N=11). Using a discriminant function with high predictive accuracy, the three groups were projected onto the corresponding feature space to identify combinations of cell populations with a trend of ALS FRS40-47 toward healthy controls. LDA plots show the distribution of each group, with the center of the x-axis indicating the point where ALS FRS21-39 and healthy controls are maximally separated, and the y-axis reflects the counts (i.e., density estimates). The title of each plot indicates the cluster in the model. The accuracy of each model is shown within the plot. [Figure 20] Results of linear discriminant analysis are shown: CD45+ cells (clusters >0.1%) healthy (n=11), ALS FRS21–39 (n=17), and ALS FRS40–47 (n=11). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0051] Detailed Description The present invention generally provides methods for defining the stages and progression of amyotrophic lateral sclerosis (ALS) and for informing clinical decision-making regarding diagnosis, therapy targeting and selection, monitoring treatment efficacy, and prognosis.

[0052] The identification of immune signatures within the clinical stages of ALS described herein allows for the development of targeted therapies and allows for the identification of patients suitable for immune cell therapy. This includes the application of specific B cell, T cell, NK cell, monocyte, dendritic cell, and mesenchymal cell therapy approaches that are personalized for each patient. The immune signatures disclosed herein and their specific changes over time serve as multi-parameter biomarkers of ALS progression or response to treatment (including anti-inflammatory / immunomodulatory / neuroimmunomodulatory approaches), and most importantly, help guide clinical decision-making. The immune signatures of ALS patients are easily applied to monitor the disease, make decisions regarding therapy application and response, predict response to therapy (both in standard care and research care settings), and identify prognostic markers of outcomes that correlate with the patient and clinical biomarkers targeted by therapy. Specifically, for these purposes, immune signature / clinical parameter (ALS-FRS score) combinations can be defined.

[0053] The present invention describes high-dimensional immunophenotypic signatures and features of patients with ALS, which are useful for diagnosis and evaluation of disease progression and treatment. Immune profiling is achieved using single or multiple omics (e.g., collection and high-throughput analysis including genomics, transcriptomics, proteomics, and metabolomics / lipidomics) techniques, including but not exclusive to flow cytometry, mass cytometry, and single-cell or total RNA sequencing, combined with clinical annotation of clinical cases. Immune signatures include the definition of specific subpopulations of B cells, T cells, NK cells, monocytes, dendritic cells, and neutrophils. In some embodiments, CyTOF methodology is utilized in conjunction with barcoding. Exemplary CyTOF methods are described in Zunder et al. (2015) Nature Protocols 10(2): 316 and Geanon et al. MedRxiv 10.1101 / 2020.06.26.20141341 (posted June 29, 2020).

[0054] The methodology is broadly as follows: 1. Placing samples of peripheral blood from patients with ALS into tubes containing anticoagulant, and collecting relevant clinical correlation information at the time of blood collection, including age, sex, date of onset of ALS, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score, hematological indices, and other individual clinical chemistry indices; 2. Separating white blood cells from blood, for example by lysing red blood cell components; 3. For example, a. Canonical markers for granulocytes, monocytes, dendritic cells, T cells, B cells, and NK cells, and b. Activation markers that characterize both immune-activating and immune-suppressing cell subpopulations, including cytokines and chemokines performing mass cytometry or flow cytometry on white blood cells using an antibody directed against; c. Using computational analysis to determine the number of immune cells in each subpopulation or cluster and their percentage of the total leukocyte population using a pan-human leukocyte marker such as CD45; 4. Total RNA sequencing on samples to define both subpopulations of leukocyte populations based on gene expression; as well as TCR and BCR expression analysis, viral genome analysis, and HLA analysis (deep HLA typing); 5. Perform computational analyses including cluster analysis, linear regression analysis, linear discriminant analysis, and elastic net logistic regression to identify clusters of leukocytes in blood samples and those that differentially distinguish healthy individuals from individuals with ALS, as well as those that differentially distinguish patients with early stage ALS (including ALS FRS scores 40-47 and 30-39).

[0055] In this scenario, if the profile includes a deficiency in regulatory or suppressive immune cell clusters (including regulatory T cells (Treg), regulatory B cells (Breg), and M2 macrophage clusters) and an increase in activated immune cell clusters T effector and B effector and NK effector cell clusters, the patient is classified as having ALS (with accompanying clinical findings) and the patient is required to start treatment with standard of care treatments for ALS such as riluzole (Rilutek, Exservan, Tiglutik kit) and / or edarabaron (Radicava), and / or sodium phenylbutyrate and taurursodiol (Relyvrio), using the approved dosing regimens for these agents.

[0056] If serial profiles from a patient show a further increase in the deficiency of immunosuppressive immune cell populations and an increase in activated immune cell clusters from the patient's initial baseline recordings, with a concomitant drop in ALSFRS-R score, the patient should be considered for immunotherapy, including immune cell therapy (B cells or Treg cells), or with appropriate immunomodulatory agents, including, for example, baracitinib (Olumiant) or other Janus kinase / signal transducer and activator of transcription (Jak-Stat) inhibitors, in clinically approved dosing.

[0057] The methods and tests described herein can be used, for example, individually or in combination with another clinical modality (e.g., ALS FRS-R) to improve and inform clinical decision-making regarding ALS diagnosis, therapy targeting and selection, monitoring of treatment efficacy, and prognosis. EXAMPLES

[0058] The following examples are presented to provide one of ordinary skill in the art with a description of how to use, make, and evaluate the compositions and methods described herein, and are intended to be merely illustrative of the disclosure and are not intended to limit the scope of what the inventors regard as their invention.

[0059] As used herein, the term "sample" when referring to a material to be tested for the presence of a biological marker using the methods of the present invention includes, inter alia, whole blood, plasma, or serum. Various methods are known within the art for the identification and / or isolation and / or purification of biological markers from a sample, if necessary.

[0060] The relative levels of each of the cell types or subsets measured in the profile are as follows: By "increase", it is meant that the level of a cell type or subset in a blood sample obtained from a tested individual (e.g., a patient) is increased by at least about 10%, preferably at least about 20%, and more preferably at least about 30%, 40%, or 50%, compared to the upper limit of its normal range level, e.g., the upper limit of the range level of the cell type or subset in a control blood sample; is represented by "decreased," which indicates that the level of a cell type or subset in a blood sample obtained from the individual being tested is decreased by at least about 10%, preferably at least about 20%, and more preferably at least about 30%, 40%, or 50% compared to the lower limit of its normal range level; or This is represented by "no change," which indicates that the level of the cell type or subset in a blood sample obtained from the individual being tested is neither increased nor decreased as defined above, e.g., is within or near its normal range level.

[0061] Although the reference profile according to the method of the present invention may be pre-determined, it is understood that the profile may be established using any suitable algorithm. For example, the representative relative levels of a particular cell type or subset to be measured may be as follows: "increased," indicating that the level of the cell type or subset in the majority of ALS patients in the group is increased compared to the normal range level of the cell type or subset; or "decreased," indicating that the level of a cell type or subset in a majority of ALS patients is decreased compared to the normal range level of the cell type or subset; or This is represented by "no change," indicating that the levels of a cell type or subset in the majority of ALS patients are neither increased nor decreased, as defined above, compared to the normal range levels of the cell type or subset.

[0062] Suitable reference value can be determined using methods known in the art, for example, using standard clinical trial methodology and statistical analysis.Reference value can have any relevant form.In some cases, reference comprises a predetermined value for the meaningful level of biomarker(s), for example, the control reference level that represents the normal level of biomarker(s), for example, the level in non-affected subject or subject that does not have the risk of developing ALS.

[0063] In some embodiments, the control subject is one who does not have ALS, is not at risk of developing ALS, or does not subsequently develop ALS. The subject is generally a healthy subject.

[0064] An ALS subject is one who has ALS (or has an increased risk of developing ALS), where increased risk is defined as a risk above that of the subject in the general population.

[0065] The levels of each of the cell types or subsets disclosed herein may be measured in the peripheral blood sample being tested using any suitable technique known in the art.

[0066] Example 1 Mononuclear cells were isolated from blood samples of 30 individuals with ALS and 15 healthy controls taken over a one-year period (Figure 1). A pilot study was performed in which PBMC samples taken from 12 ALS patients and 6 age- and sex-matched healthy controls were labeled with metal-conjugated antibodies and profiled by mass cytometry (CyTOF - time-of-flight cytometry) (Figure 2).

[0067] The pilot study protocol was as follows: Frozen PBMCs were thawed; 2 million live PBMCs were labeled for CyTOF analysis. • Each patient was surface labeled with a unique “barcode.” The barcode is a unique combination of three metal tags. The metal-binding antibodies used for the barcode are: ■CD45 194Pt, CD45 195Pt, CD45 196Pt, CD45 198Pt, CD45 89Y; ■B2M 194Pt, B2M 195Pt, B2M 196Pt, B2M 198Pt, B2M 11Cd; and ■CD298 195Pt, CD298 196Pt, CD298 198Pt, CD298 112Cd. After barcoding, samples were pooled; surface and intracellular markers were labeled; and data was acquired on a Helios Cytometer following standard methods.

[0068] Data analysis (see, e.g., FIG. 3) was performed as follows: ● Debarcode the data and identify each individual sample using manual gates; The debarcoded data was clustered using X-Shift. ●X-shift computes density estimates for each data point. It then searches for local density maxima in the nearest neighbor graph, which become cluster centroids. Then all remaining data points in the graph are connected to the centroids via density ascending paths, thereby forming clusters. For B cells, independent clustering was performed using X-Shift. • Number of phenotypic clusters in all CD45+ cells = 52. • Number of phenotypic clusters in B cells = 19.

[0069] result: The results of Example 1 are described above and can be seen in Figures 3 through 15. These results are summarized below.

[0070] A. B Cell Subpopulations of Interest: Logistic regression models identified a higher probability of lower abundance of FoxP3+B regulatory cells in peripheral blood of ALS patients. Linear discriminant analysis revealed that mature B cells (IgD+ IgM+) with CD11c expression were increased in patients with lower ALSFRS-R compared to higher ALSFRS-R and healthy controls (model accuracy = 0.60).

[0071] B. T cell subpopulations of interest: Logistic regression models identified activated CD4 and CD8 T cell subtypes as more likely to be abundant in peripheral blood of ALS patients compared to healthy controls. Linear discriminant analysis revealed that activated CD4 T cells were elevated in patients with lower ALSFRS-R compared to patients with higher ALSFRS-R and healthy controls (model accuracy = 0.75).

[0072] C. Natural Cell Subpopulations of Interest: Logistic regression models identified CD11c+ monocytes and NK T cells as having a higher probability of being abundant in the peripheral blood of ALS patients compared with healthy controls.

[0073] Due to the small number of patients studied and the large variability in immune profiles, predictive models were used to identify clusters of interest.

[0074] Example 2 A second study was performed on PBMC samples taken from 30 ALS patients and 15 age- and sex-matched healthy controls. Cells were labeled with metal-conjugated antibodies and profiled by mass cytometry (CyTOF). The mean age at time of sample collection was 56.12 (standard deviation = 11.11). The mean ALS Functional Rating Scale-Revised score (ALSFRS-R) of the ALS cohort was 36.5 (standard deviation = 6.6). Data acquired from CyTOF were clustered using k-means.

[0075] The complete CyTOF test protocol was as follows: Frozen PBMCs were thawed; 2 million live PBMCs were labeled for CyTOF analysis. • Each patient was surface labeled with a unique “barcode.” The barcode is a unique combination of three metal tags. The metal-binding antibodies used for the barcode are: ■CD45 194Pt, CD45 195Pt, CD45 196Pt, CD45 198Pt, CD45 89Y; ■B2M 194Pt, B2M 195Pt, B2M 196Pt, B2M 198Pt, B2M 11Cd; and ■CD298 195Pt, CD298 196Pt, CD298 198Pt, CD298 112Cd. After barcoding, samples were pooled; surface and intracellular markers were labeled; and data was acquired on a Helios Cytometer.

[0076] Data analysis was performed as follows: • The data was debarcoded and each individual sample was identified using manual gates. • The debarcoded data was clustered using k-means clustering. The study identified approximately 92 clusters using unique expression of 37 CyTOF variables. • Cell clusters were assessed for differences between ALS patients and healthy controls via t-tests and logistic regression.

[0077] result: The results of Example 1 are described above and can be seen in Figures 16-20. These results are summarized below.

[0078] A. B Cell Subpopulations of Interest: Due to the relatively small number of patients in the study, it was necessary to utilize predictive models to identify clusters of interest. Activated B cells (CD19+ CD20+ IgD+ IgM+) and memory B cells (CD19+ CD20+ CD21+ CD27+) were more likely to be present in lower abundance in the peripheral blood of ALS patients.

[0079] B. T cell subpopulations of interest: Compared to healthy controls, ALS patients have significantly increased activated CD4 T cell (CD27+ PD1+) and CD8 T cell (CD27+ CD7+) populations. Due to the relatively small number of patients in the study, it was necessary to utilize a predictive model to identify clusters of interest. Within our training model, activated CD4 T cell (CD27+ PD1+) and CD8 T cell (CD27+ CD7+) populations were identified as having a higher probability of being more abundant in peripheral blood of ALS patients. Linear discriminant analysis identified a CD4 T cell population (CD25+ CD27+ CD39+) that is more expressed in patients with lower ALSFRS-R compared to patients with higher ALSFRS-R and healthy controls (accuracy=0.77).

[0080] C. Natural Cell Subpopulations of Interest: Exploratory logistic regression models identified only NK T cells as having a higher probability of being abundant in the peripheral blood of ALS patients compared with healthy controls.

[0081] The findings of the full-scale study (Example 2) are consistent with the results obtained during the pilot study (Example 1). These clearly identified immune subpopulation differences will be a clinical decision-making tool that will help indicate when to initiate standard care and what specific therapy (anti-inflammatory / immunomodulatory or other) should be administered, and when to intervene with such therapy during the course of the patient's disease. This may be the first biomarker signature that can be used as a clinical decision-making tool that seems to be sufficient to surpass the previously elusive single chemical biomarkers of disease progression in ALS.

[0082] The immune signatures of the present invention can be used in a variety of ways, including: 1. Monitoring The immune profile changes over the course of the disease. Correlation analysis between immune phenotype and ALSFRS-R may indicate the appropriate timing of treatment with immunomodulatory or immune cell therapy. 2. Predictive biomarkers Immune signature profiling guides the timing and patient selection for any given immunotherapy. 3. Prognosis Prognostic biomarkers predict disease outcome and tend to remain the same throughout the course of the disease. For example, neurofilament rises in rapid progression. It rises early and stays there. This means that it is not a good monitoring biomarker. Immune profiling gives a flexible signature that can act as a disease monitoring biomarker. So far, we have demonstrated differences between the immune profiles of patients with early and late ALS based on ALSFRS-R score. 4.PD / Drug Response Immune signatures can be good pharmacodynamic (PD) / response biomarkers for clinical trials. This goes hand in hand with being a monitoring biomarker. It can be a PD biomarker for immunotherapy even if it fails to monitor the disease. This is especially true when compared to modern subjective and qualitative clinical function scores such as the ALS-FRS score, or individual biochemical indices including neurofilament measurements in serum or CSF.

[0083] Other Aspects While the present invention has been described in connection with its detailed description, it will be understood that the foregoing description is intended to be illustrative and not limiting of the scope of the invention, which is defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

[0084] Other aspects are included in the following numbered paragraphs. 1. A method for diagnosing ALS in a patient, comprising: (a) performing mass cytometry on a sample of white blood cells obtained from the patient's peripheral blood using antibodies directed against (i) canonical markers for granulocytes, monocytes, dendritic cells, T cells, B cells, and NK cells; and (ii) activation markers that characterize both immune-activated and immune-inhibitory cell subpopulations, including cytokines and chemokines; (b) applying computational analysis to determine the number of immune cells of each subpopulation or cluster and their proportion of the total leukocyte population, using the pan-human leukocyte marker CD45; (c) performing total RNA sequencing on said patient samples to define both subpopulations of leukocyte populations based on gene expression; and TCR and BCR expression analysis, viral genome analysis, and HLA analysis (deep HLA typing); (d) Analytical steps and elastic net logistic regression to identify clusters of leukocytes in said patient samples; and clusters of specific subpopulations of immune and inflammatory cell populations that differentially distinguish healthy individuals from individuals with early or late stage ALS based on FRS-R score. where (I) if the patient sample contains a deficiency in regulatory or suppressive immune cell clusters including Treg, Breg, M2 macrophage clusters, and an increase in activated immune cell clusters T effector and B effector and NK effector cell clusters, the patient is considered to have ALS and requires initiation of riluzole and / or edarabaron using an approved dosing regimen for these agents, and if the patient sample does not contain the deficiency and increase in the activated immune cell clusters, the patient is unlikely to have ALS and no drug administration is required.

[0085] 2. A method for assessing the progression of ALS in a patient and determining an appropriate treatment, comprising: (a) using the method of claim 1 to determine whether the patient has ALS; (b) obtaining serial samples of white blood cells from the patient's peripheral blood and subjecting those samples to the method of claim 1, If serial profiles from the patient show a further increase in the deficiency of immunosuppressive immune cell populations and an increase in activated immune cell clusters from the initial baseline recording in the patient with a concomitant drop in ALSFRS-R score, the patient is considered for immunotherapy, including immune cell therapy (B cells or Treg cells), in clinically approved dosages, or immunomodulatory agents, including, for example, baracitinib or other Jak-Stat inhibitors, or other repurposed or novel drugs, or cell therapies under investigation for use in ALS. The method comprising:

Claims

1. 1. A method comprising the step of characterizing a white blood cell sample from a patient using cytometry, The method, wherein a deficiency in regulatory or suppressive immune cells and an increase in activated immune cells in the sample compared to a healthy sample indicates that the patient has amyotrophic lateral sclerosis (ALS).

2. 10. The method of claim 1, wherein the sample is incubated with an antibody that specifically binds to granulocytes, monocytes, dendritic cells, T cells, B cells, NK cells, immune-activating cells, or immune-inhibitory cells.

3. The method of claim 1, wherein the regulatory or suppressive immune cells comprise Treg, Breg, or M2 macrophage clusters.

4. The method of claim 1, wherein the activated immune cells include T effector and B effector and NK effector cell clusters.

5. 3. The method of claim 2, further comprising calculating the number of immune cells and their percentage of the total white blood cell population of the sample using a pan-human white blood cell marker.

6. The method of claim 5, wherein the pan-human leukocyte marker is CD45.

7. The method of claim 1, wherein the cytometry is cell or mass cytometry.

8. The method of claim 1, comprising the steps of: performing total RNA sequencing on the sample to define subpopulations of the leukocyte population; and performing TCR and BCR expression analysis, viral genome analysis, and / or HLA analysis.

9. 10. The method of claim 1, further comprising identifying clusters of white blood cells in the sample.

10. 10. The method of claim 9, wherein the identifying step comprises cluster analysis, linear regression analysis, linear discriminant analysis, and / or elastic net logistic analysis.

11. 11. The method of claim 10, wherein the clusters of white blood cells distinguish between healthy individuals and individuals with ALS.

12. 12. The method of claim 11, wherein the ALS is late stage ALS or early stage ALS.

13. The method of claim 1, wherein the patient has a deficiency in Treg, Breg, or M2 macrophage clusters.

14. The method of claim 1, wherein the patient has an increase in activated immune cell clusters, T effector and B effector.

15. The method of claim 1, wherein the patient has an increase in activated NK effector clusters.

16. 10. The method of claim 1, further comprising administering to the patient a therapy for treating ALS.

17. 17. The method of claim 16, wherein the therapy is riluzole or edarvarone.

18. 2. The method of claim 1, wherein FoxP3+B regulatory cells are less abundant in ALS patients.

19. The method of claim 1, wherein mature B cells comprising CD11c expression are increased in patients with lower ALSFRS-R compared to higher ALSFRS-R and healthy controls.

20. The method of claim 1, wherein CD4 T cells are increased in the ALS patient.

21. The method of claim 1, wherein CD8 T cells are increased in the ALS patient.

22. The method of claim 1, wherein activated CD4 T cells are elevated in ALS patients with lower ALSFRS-R compared to patients with higher ALSFRS-R and healthy controls.

23. The method of claim 1, wherein CD11c+ monocytes are increased in ALS patients.

24. The method of claim 1, wherein NK T cells are increased in the ALS patient.

25. The method of claim 1, wherein activated B cells (CD19+ CD20+ IgD+ IgM+) are decreased in ALS patients.

26. The method of claim 1, wherein memory B cells (CD19+ CD20+ CD21+ CD27+) are decreased in ALS patients.

27. The method of claim 1, wherein activated CD4 T cells (CD27+ PD1+) are increased in ALS patients.

28. The method of claim 1, wherein CD8 T cells (CD27+ CD7+) are increased in ALS patients.

29. The method of claim 1, wherein CD4 T cells (CD25+ CD27+ CD39+) are increased in ALS patients with lower ALSFRS-R compared to ALS patients with higher ALSFRS-R and healthy controls.

30. The method of claim 1, wherein NK T cells are increased in the ALS patient.

31. The method of claim 1, comprising determining the levels of at least two, three, four, five, six, seven, eight, nine, ten, eleven, twelve or more markers as described in Figures 2, 8B, 10B, 12, 14B, and 15B.

32. 2. The method of claim 1, wherein the sample comprises a phenotype depicted in cluster 387, 392, 394, 408, or 422.

33. 2. The method of claim 1, wherein the sample comprises a phenotype depicted in clusters 951, 947, 961, 953, 945, 955, 954, 949, 944, 956, or 962.

34. 2. The method of claim 1, wherein the sample comprises a phenotype depicted in cluster 21, 28, 44, 92, or 37.

35. (a) determining whether a patient has ALS according to any one of the preceding claims; (b) analyzing a second white blood cell sample from the patient according to any one of the preceding claims; and (c) determining a deficiency in regulatory or suppressor immune cells and an increase in activated immune cells in the second sample. A method comprising:

36. 36. The method of claim 35, wherein the patient has an increased deficiency of Treg, Breg, or M2 macrophage clusters in the second sample compared to the sample of claim 1.

37. 36. The method of claim 35, wherein the patient has an increase in activated immune cell clusters T effector and B effector in the second sample compared to the sample of claim 1.

38. The method of claim 35, wherein the patient has an increase in activated NK effector clusters in the second sample compared to the sample of claim 1.

39. 36. The method of claim 35, further comprising administering to the patient a therapy for treating the ALS.

40. 40. The method of claim 39, wherein the therapy comprises immune cell therapy.

41. 41. The method of claim 40, wherein the immunotherapy comprises administering B cells or Treg cells.

42. 40. The method of claim 39, wherein the therapy comprises administering an immunomodulatory agent.

43. 43. The method of claim 42, wherein the immunomodulatory agent is Baracitinib or a Jak-Stat inhibitor.

44. 36. The method of claim 35, wherein the patient has experienced a clinically meaningful decline from baseline in ALSFRS-R total score at the time the second sample is obtained.

45. 36. The method of claim 35, wherein there is at least 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, or 14 weeks between obtaining the sample of claim 1 and the second sample.

46. The method of any one of claims 1 to 45, wherein the patient is a human.

47. 1. A method of treating ALS, comprising: performing flow cytometry using a blood sample obtained from the human according to the method of claims 1 to 15 and 18 to 35 to identify the human as having ALS; and administering an ALS therapy to said human. The method comprising:

48. 1. A method of treating ALS, comprising: administering a therapy to an ALS patient identified as having ALS according to the method of claims 1-15 and 18-35. The method comprising:

49. 48. The method of claim 47, wherein the ALS therapy involves administering riluzole or edavarone.

50. 49. The method of claim 48, wherein the therapy comprises immune cell therapy.

51. 49. The method of claim 48, wherein the therapy comprises administering an immunomodulatory agent.

Citation Information

Patent Citations

  • How to Treat Amyotrophic Lateral Sclerosis (ALS)

    JP2019527218A

  • Composite Profiles of Cell Antigens and Target Signal Transduction Proteins for Analysis and Clinical Management of Hematologic Cancers

    US20100261204A1

  • Monitoring health and disease status using clonotype profiles

    US20180080090A1

  • Methods for treating amyotrophic lateral sclerosis

    US20200046705A1

  • Immune Monitoring of Neuro-Inflammatory Amyotrophic Lateral Sclerosis (ALS)

    US20210270843A1